Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death

BACKGROUND: The ST6Gal-I sialyltransferase is upregulated in numerous cancers, and high expression of this enzyme correlates with poor patient prognosis in various malignancies, including ovarian cancer. Through its sialylation of a select cohort of cell surface receptors, ST6Gal-I modulates cell si...

Descripción completa

Detalles Bibliográficos
Autores principales: Britain, Colleen M., Holdbrooks, Andrew T., Anderson, Joshua C., Willey, Christopher D., Bellis, Susan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800010/
https://www.ncbi.nlm.nih.gov/pubmed/29402301
http://dx.doi.org/10.1186/s13048-018-0385-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800010/
https://www.ncbi.nlm.nih.gov/pubmed/29402301
http://dx.doi.org/10.1186/s13048-018-0385-0

Ejemplares similares